1,3-Disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
申请人:——
公开号:US20020035103A1
公开(公告)日:2002-03-21
Compounds of formula I
1
are useful in treating diseases or conditions prevented by or ameliorated with histamine-3 receptor ligands. Also disclosed are histamine-3 receptor ligand compositions and methods of antagonizing or agonizing histamine-3 receptors.
1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
申请人:——
公开号:US20020137931A1
公开(公告)日:2002-09-26
Compounds of formula I
1
are useful in treating diseases or conditions prevented by or ameliorated with histamine-3 receptor ligands. Also disclosed are histamine-3 receptor ligand compositions and methods of antagonizing or agonizing histamine-3 receptors.
Histamine-3 receptor ligands for diabetic conditions
申请人:——
公开号:US20030153548A1
公开(公告)日:2003-08-14
The invention relates to a method of treating a diabetic condition by administering a therapeutically effective amount of a histamine-3 receptor antagonist, including benzofuran and benzopyran derivatives of formula (I), aminoalkoxybiphenylcarboxamide compounds of formula (III), and aminoetherbiphenyl compounds of formula (IV) as described herein.
Histamine-3 receptor ligands for diabetes conditions
申请人:——
公开号:US20030134835A1
公开(公告)日:2003-07-17
The invention relates to a method of treating a diabetic condition by administering a therapeutically effective amount of a histamine-3 receptor antagonist, including benzofuran and benzopyran derivatives of formula (I), aminoalkoxybiphenylcarboxamide compounds of formula (III), and aminoetherbiphenyl compounds of formula (IV) as described herein.
[EN] HISTAMINE-3 RECEPTOR LIGANDS FOR DIABETIC CONDITIONS<br/>[FR] LIGANDS DE RECEPTEUR D'HISTAMINE-3 POUR TRAITER DES ETATS DIABETIQUES
申请人:ABBOTT LAB
公开号:WO2003059342A1
公开(公告)日:2003-07-24
The invention relates to a method of treating a diabetic condition by administering a therapeutically effective amount of a histamine-3 receptor antagonist, including benzofuran and benzopyran derivatives of formula (I), aminoalkoxybiphenylcarboxamide compounds of formula (III), and aminoetherbiphenyl compounds of formula (IV) as described herein.